Effects of Lactobacillus paracasei N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis

• Published in: World journal of gastroenterology : WJG 2024-03, Vol.30 (11), p.1556-1571
• Main Authors: Hu, Yan-Chao, Ding, Xiang-Chun, Liu, Hui-Juan, Ma, Wan-Long, Feng, Xue-Yan, Ma, Li-Na
• Format: Article
• Language: English
• Subjects: Clinical Trials Study; Gastrointestinal Microbiome; Hepatitis B; Humans; Lacticaseibacillus paracasei; Liver Cirrhosis - diagnosis
• ISSN: 1007-9327; 2219-2840; 2219-2840
• DOI: 10.3748/wjg.v30.i11.1556

Hepatitis B cirrhosis (HBC) is a chronic disease characterized by irreversible diffuse liver damage and aggravated by intestinal microbial imbalance and metabolic dysfunction. Although the relationship between certain single probiotics and HBC has been explored, the impact of the complex ready-to-eat N1115 (LP N1115) supplement on patients with HBC has not been determined. To compare the changes in the microbiota, inflammatory factor levels, and liver function before and after probiotic treatment in HBC patients. This study included 160 HBC patients diagnosed at the General Hospital of Ningxia Medical University between October 2018 and December 2020. Patients were randomly divided into an intervention group that received LP N1115 supplementation and routine treatment and a control group that received routine treatment only. Fecal samples were collected at the onset and conclusion of the 12-wk intervention period. The structure of the intestinal microbiota and the levels of serological indicators, such as liver function and inflammatory factors, were assessed. Following LP N1115 intervention, the intestinal microbial diversity significantly increased in the intervention group ( < 0.05), and the structure of the intestinal microbiota was characterized by an increase in the proportions of probiotic microbes and a reduction in harmful bacteria. Additionally, the intervention group demonstrated notable improvements in liver function indices and significantly lower levels of inflammatory factors ( < 0.05). LP N1115 is a promising treatment for ameliorating intestinal microbial imbalance in HBC patients by modulating the structure of the intestinal microbiota, improving liver function, and reducing inflammatory factor levels.